Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
PR Newswire · 4d ago
Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
PR Newswire · 11/19 12:30
Actinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be participating in the Alliance Global Partners' Virtual Healthcare Symposium being held on Thursday, November 19, 2020. During the event, Actinium's Chief Medical Officer Mark Berger will participate in a panel discussing emerging trends in hematology ahead of the American Society of Hematology (ASH) Annual Meeting being held December 5th – 8th. Actinium's Antibody Radiation Conjugates, Iomab-B and Actimab-A, will be featured in three oral presentations at ASH, two focused on the pivotal Phase 3 SIERRA trial for Iomab-B and one on the Actimab-A CLAG-M combination trial, as well as poster presentation of the Actimab-A venetoclax combination trial. Actinium's ASH abstracts can be accessed here: https://ashpublications.org/blood/issue/136/Supplement%201
PR Newswire · 11/16 12:00
Actinium Pharma Reports 100% Of Evaluable Patients In Third, Planned Final Dose Cohort Of Actimab-A CLAG-M Phase 1 Trial Being Conducted At Medical College Of Wisconsin Achieved Remission
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at
Benzinga · 11/04 17:23
Actinium Pharma Highlights Poster Presentation At American Society Of Hematology Accepted For Actimab-A Venetoclax Data
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that data from the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial, has been accepted for poster presentation
Benzinga · 11/04 17:03
Actinium Pharma Gives Corporate Update Covering Progress Made In 2020
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company") today provided a corporate update covering the progress made in 2020 thus far as well as major milestones expected by
Benzinga · 10/28 11:17
Actinium Pharma cheers National Institutes of Health grant to study novel Iomab-ACT
National Institutes of Health awarded Actinium Pharmaceuticals (ATNM) +6% PM, a Small Business Technology Transfer grant to support a clinical collaboration with Memorial Sloan Kettering ((MSK)) Cancer Center to study Iomab-ACT, Actinium's
Seekingalpha · 10/21 12:58
Actinium Pharma Wins Grant By National Institutes Of Health To Study Novel Iomab-ACT Targeted Conditioning With CD19 CAR T-Cell Therapy, No Terms Disclosed
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company") today announced that the National Institutes of Health has awarded Actinium a Small Business Technology Transfer grant to
Benzinga · 10/21 11:11
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the National Institutes of Health has awarded Actinium a Small Business Technology Transfer grant to support a clinical collaboration with Memorial Sloan Kettering Cancer Center ("MSK") to study Iomab-ACT, Actinium's CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. The CD19 CAR-T has been previously studied by MSK in a Phase 2 trial with chemotherapy conditioning in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) or diffuse large B-cell lymphoma (DLBCL). MSK will lead this first of its kind study to utilize targeted radiopharmaceutical ARC-based lymphodepletion to replace chemotherapy-based conditioning prior to CAR T-cell therapy. The study will assess the feasibility of using Iomab-ACT targeted lymphodepletion prior to MSK's 19-28z CAR-T and assess safety and efficacy outcomes relative to results with MSK's CAR-T 19-28z in patients who had received chemotherapy-based lymphodepletion prior to CAR-T administration.
PR Newswire · 10/21 11:00
Actinium Pharmaceuticals expands R&D capabilities with new research facility in New York City
Actinium Pharmaceuticals ([[ATNM]] +0.9%) announces the launch of its new research and development lab facility in New York City."Our new research facility will allow us to significantly accelerate our preclinical
Seekingalpha · 10/14 14:10
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal R&D capabilities and will be focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations. Actinium's R&D efforts will employ a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development. The proprietary AWE technology platform, protected by over one hundred and twenty-five patents, is the foundation for Actinium's R&D and exploits multiple different radioisotope payloads including the potent alpha-emitter, Actinium-225.
PR Newswire · 10/14 11:00
Actinium concludes dosing cohort in Phase 1 Actimab-A/venetoclax combination trial
Actinium Pharmaceuticals (ATNM) has completed the first dosing cohort in the Actimab-A + venetoclax combination, in Phase 1 trial for patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). The
Seekingalpha · 09/23 13:22
Actinium Pharmaceuticals: Far Enough Along For A Small Bet
Their targeted approach to bone marrow transplant conditioning has shown early signs of significantly improving on the poor outcomes seen with current non-targeted therapies. The early nature of the data and the high likelihood of several future rounds of dilutive financing prevent this from being a top pick. Still, the promising results thus far justify a small bet.
Seekingalpha · 09/22 20:00
Actinium Pharmaceuticals Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (the "Company" or "Actinium") today provided an update on the Actimab-A CLAG-M combination Phase 1 trial being conducted at the Medical College of Wisconsin ("MCW") in patients with Relapsed or Refractory ("R/R"
PR Newswire · 09/14 11:00
LD Micro: 360 Companies Set to Present this Week
ACCESSWIRE · 08/31 23:05
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Is (ATNM) Outperforming Other Medical Stocks This Year?
Zacks · 08/28 16:30
Is a Surprise Coming for Actinium Pharmaceuticals (ATNM) This Earnings Season?
Actinium Pharmaceuticals (ATNM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 08/26 12:48
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
Zacks · 08/12 16:30
Actinium Pharmaceuticals, Inc. Announces Reverse Stock Split
PR Newswire · 08/10 19:30
Actinium Pharmaceuticals announces reverse stock split 1-for-30
Seeking Alpha - Article · 08/10 18:56
Webull provides a variety of real-time ATNM stock news. You can receive the latest news about ACTINIUM PHARMAC through multiple platforms. This information may help you make smarter investment decisions.
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.More